CHRS stock

Coherus BioSciences Inc (CHRS) financials · rev $26.6M

Coherus BioSciences Inc (CHRS) rev $26.6M.

Cached annual income statement
LineFY2025FY2024
Revenue$42.2M$267.0M
Cost of Revenue$13.8M$117.6M
Gross Profit$28.4M$149.4M
Operating Income-$181.1M-$111.7M
Net Income$168.0M$28.5M
EPS (Diluted)$1.43$0.25
Cached annual balance sheet
LineFY2025FY2024
Total Assets$258.3M$448.5M
Current Assets$206.7M$341.6M
Cash & Equivalents$88.9M$126.0M
Inventory$3.2M$70.1M
PP&E$1.3M$2.8M
Total Liabilities$197.3M$580.5M
Current Liabilities$140.4M$283.0M
Short-term Debt$0$0
Long-term Debt$0$0
Total Debt$0$0
Shareholders' Equity$61.0M-$132.0M
Retained Earnings-$1.38B-$1.55B
Cached annual cash flow
LineFY2025FY2024
Operating Cash Flow-$138.5M-$20.4M
CapEx$0$0
Investing Cash Flow$375.1M$230.3M
Financing Cash Flow-$273.7M-$187.0M
Dividends Paid$0$0
Net Change in Cash-$37.1M$0
Free Cash Flow$0$0

FAQ

What is CHRS P/E and revenue?

Coherus BioSciences Inc (CHRS) rev $26.6M.

What is CHRS revenue?

Coherus BioSciences Inc last cached revenue is $42.2M (FY2025).

Is CHRS profitable?

Coherus BioSciences Inc last cached net income is $168.0M.

What are CHRS total assets?

Coherus BioSciences Inc last cached total assets are $258.3M.

What is CHRS free cash flow?

Coherus BioSciences Inc last cached free cash flow is $0.

Not investment advice. Cached statements, not a live tape.